DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Aloxiprin

Aloxiprin

  • Characterising the Risk of Major Bleeding in Patients With

    Characterising the Risk of Major Bleeding in Patients With

  • Choice of Drugs in the Treatment of Rheumatoid Arthritis

    Choice of Drugs in the Treatment of Rheumatoid Arthritis

  • 18 Analgesics Anti-Inflammatory Drugs and Antipyretics the Dosage of Alfentanil Used Depends on Whether the 2

    18 Analgesics Anti-Inflammatory Drugs and Antipyretics the Dosage of Alfentanil Used Depends on Whether the 2

  • Bleeding Disorders of Importance in Dental Care and Related Patient Management

    Bleeding Disorders of Importance in Dental Care and Related Patient Management

  • Study Protocol

    Study Protocol

  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

  • CHAPTER 1 General Introduction

    CHAPTER 1 General Introduction

  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös

    Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös

  • (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher Et Al

    (12) United States Patent (10) Patent No.: US 8,835,407 B2 Mosher Et Al

  • ( 12 ) United States Patent

    ( 12 ) United States Patent

  • Pharmaceutical Appendix to the Harmonized Tariff

    Pharmaceutical Appendix to the Harmonized Tariff

  • WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T

    WO 2013/020527 Al 14 February 2013 (14.02.2013) P O P C T

  • CUSTOMS TARIFF - SCHEDULE 99 - I

    CUSTOMS TARIFF - SCHEDULE 99 - I

  • Head Injury Partial Update

    Head Injury Partial Update

  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……

    Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……

  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes

  • Project SCYLLA

    Project SCYLLA

  • Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting

    Systemic Glucocorticoids in the Treatment of COVID-19 and Risks of Adverse Outcomes in COVID-19 Patients in the Primary and Secondary Care Setting

Top View
  • Nmr Methods for Monitoring Blood Clot Formation
  • Inhibition of Platelet Release Reaction by Acetylsalicylic Acid RL RENTON* GA Mcdonald SJ CORNE
  • Salicylate in Man by Carole Bedford, A
  • The Effect of 3-Methyl Salicylic (0-Cresotinic) Acid on Plasma
  • Pharmacological Interventions for the Prevention of Fetal Growth Restriction: Protocol for a Systematic Review and Network Meta-Analysis
  • Bleeding Disorders of Importance in Dental Care
  • Supplementary Material 1. String for MEDLINE Search. 1
  • Pharmaceutical Compositions Comprising Prasugrel And
  • Pharmaabkommen A1 E
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
  • Today's Drugs
  • Customs Tariff - Schedule Xxi - 1
  • Pharmaceutical Appendix to the Tariff Schedule 2
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
  • (12) United States Patent (10) Patent No.: US 9.474,831 B2 Boyden Et Al
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
  • Pharmaceutical Appendix to the Tariff Schedule 2


© 2024 Docslib.org    Feedback